NCT03038022Phase 2Completed

Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Study sponsor: Madrigal Pharmaceuticals, Inc. · MDGL

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2018-01-15Actual
Enrollment · participants116Actual
Source updated2026-06-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Mean Percentage Change in LDL-C From Baseline To Week 12. After: Measure: Mean Percent Change in LDL-C From Baseline To Week 12.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview